2. Academic Validation
  3. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

  • ACS Med Chem Lett. 2017 Jan 23;8(3):321-326. doi: 10.1021/acsmedchemlett.6b00491.
Brian Metcalf 1,  Chihyuan Chuang 2,  Kobina Dufu 1,  Mira P Patel 1,  Abel Silva-Garcia 1,  Carl Johnson 1,  Qing Lu 2,  James R Partridge 1,  Larysa Patskovska 3,  Yury Patskovsky 3,  Steven C Almo 3,  Matthew P Jacobson 4,  Lan Hua 4,  Qing Xu 1,  Stephen L Gwaltney 2nd 1,  Calvin Yee 1,  Jason Harris 1,  Bradley P Morgan 2,  Joyce James 2,  Donghong Xu 2,  Athiwat Hutchaleelaha 1,  Kumar Paulvannan 5,  Donna Oksenberg 1,  Zhe Li 1
Affiliations

Affiliations

  • 1 Global Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
  • 2 Cytokinetics, Inc. , South San Francisco, California 94080, United States.
  • 3 Albert Einstein College of Medicine , Bronx, New York 10461, United States.
  • 4 Department of Pharmaceutical Chemistry, University of California , San Francisco, California 94158, United States.
  • 5 Tandem Sciences, Inc. , Menlo Park, California 94025, United States.
PMID: 28337324 DOI: 10.1021/acsmedchemlett.6b00491
Abstract

We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ∼150. This partitioning onto the target protein is anticipated to allow therapeutic concentrations to be achieved in the red blood cell at low plasma concentrations. GBT440 (36) is in Phase 3 clinical trials for the treatment of sickle cell disease (NCT03036813).

Keywords

Schiff-base formation; Sickle cell disease; aldehyde; allosteric modulator; oxygen affinity; red blood cell partitioning; sickle cell hemoglobin.

Figures
Products